{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-22-000130","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.323073+00:00","generated_at":"2026-06-26T03:39:46.590922+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lilly Q1 2022 revenue up 15% to $7.81B; reported EPS $2.10, non-GAAP $2.62; raises guidance","bullets":["Revenue $7.81B (+15% YoY); volume growth 20%; core product sales up 13 ppt.","Reported EPS $2.10 (+41%); non-GAAP EPS $2.62 (+63%); both include $0.15 charges.","2022 EPS guidance raised: reported $7.30-$7.45; non-GAAP $8.15-$8.30.","Tirzepatide SURMOUNT-1 obesity Phase 3: up to 22.5% weight loss; 63% of high-dose group lost ≥20% body weight.","FDA accepted mirikizumab submission for UC; Jardiance EMPA-KIDNEY trial stopped early for positive efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-22-000130","json":"https://secwatch.observer/filing/0000059478-22-000130.json","markdown":"https://secwatch.observer/filing/0000059478-22-000130.md","text":"https://secwatch.observer/filing/0000059478-22-000130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000130/0000059478-22-000130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000130/lly-20220428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:39:46.590922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}